Clinical trials: Multiple Sclerosis - Relapsing Remitting, open to volunteers
Multiple Sclerosis (MS) Relapsing Remitting
Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis
The purpose of this study is to assess the immediate effects of a commercially available non-FDA regulated powered hip flexion assist device (Hypershell X, Shenzhen, China) on walking ability in persons with MS.
- Trial name
- NCT07724093
- Testing
- Powered Hip Flexion Orthosis (Hypershell X)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Dayton
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis
The goal of this clinical trial is to learn whether a structured lifestyle program can improve health and wellbeing in people living with multiple sclerosis (MS).
- Trial name
- HEAL-MS (NCT07589062)
- Testing
- Multi-Domain Lifestyle Intervention
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- New York University Abu Dhabi
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to <18 years with RRMS.
- Trial name
- Operetta III (NCT07503340)
- Testing
- Ocrelizumab co-formulated with rHuPH20
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis (RRMS)
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage.
- Trial name
- TWINS (NCT06663189)
- Testing
- treatment withdrawal, Usual DMT continuation, MRI
- Where
- 22 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost.
- Trial name
- DESIRE MS (NCT07189325)
- Testing
- Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis, Relapsing-Remitting
TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
Centra nervous system (CNF) damage in multiple sclerosis (MS), are mainly attributed to myelin destruction, axonal abnormalities and subsequent degeneration, and are responsible for serious deficiencies.
- Trial name
- TOTEM-RRMS (NCT03910738)
- Testing
- Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection, MRI, Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
- Where
- 5 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Strasbourg, France
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
The goal of this clinical trial is to evaluate the safety and tolerability of terfenadine when added to standard first-line disease-modifying therapy in adults with multiple sclerosis.
- Trial name
- NCT07827716
- Testing
- Terfenadine, Standard First-line Disease-Modifying Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chuan Qin
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Investigation of Subclinical Markers of Multiple Sclerosis
Transcranial magnetic stimulation (TMS) studies reported consistent and substantial impairments in the central nervous system (CNS) in multiple sclerosis (MS).
- Trial name
- SUBCLIN-MS (NCT04604041)
- Testing
- 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA
- Where
- Croatia
- Volunteers
- 50 people
- Sponsor
- University of Split, School of Medicine
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting
Intermittent Hypoxia in Persons With Multiple Sclerosis
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06276634
- Testing
- Acute Intermittent Hypoxia
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis
The prevalence of sexual dysfunction is higher among women with multiple sclerosis (MS) than women in the general population. The presence of sexual dysfunction is associated with decreased well-being and quality of life.
- Trial name
- BIPAMS-SD (NCT04768777)
- Testing
- Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Relapsing Remitting Multiple Sclerosis
Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years.
- Trial name
- FILYRA (NCT06949956)
- Volunteers
- 140 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Multiple Sclerosis (MS) - Relapsing-remitting
Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Morphology in Individuals With Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is a chronic neurological disease associated with reduced muscle strength, impaired mobility, increased fatigue, and deterioration in muscle morphology.
- Trial name
- RRMS-BFR (NCT07645937)
- Testing
- Blood Flow Restriction Training, Low-Load Exercise Program
- Volunteers
- 30 people
- Sponsor
- Hanifi Bal
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis
This interventional, randomized, sham-controlled study will examine whether Acute Intermittent Hypoxia (AIH) delivered immediately before Myoelectric Interface Neurorehabilitation Training (MINT)-based locomotor training improves…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- MINT (NCT07631923)
- Testing
- Acute Intermittent Hypoxia (AIH), Myoelectric Interface Neurorehabilitation Training (MINT)
- Volunteers
- 35 people
- Sponsor
- Shirley Ryan AbilityLab
Relapsing Remitting Multiple Sclerosis
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT06796504
- Testing
- Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- SetPoint Medical Corporation
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
MS-ResearchBiomarkerS
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MS-ReBS (NCT05204459)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy…
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- BEAT-MS (NCT04047628)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Where
- 23 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, RRMS
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy.
- Conditions
- Multiple Sclerosis, RRMS, Relapsing Remitting MS
- Trial name
- MIIMS (NCT07510607)
- Testing
- HP 13C pyruvate injection, MRI Scanner
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ari Green
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery
The goal of this clinical trial is to learn if stimulating the vagus nerve in combination with a motor task in people with multiple sclerosis can improve motor function.
- Trial name
- NCT06641271
- Testing
- Closed Loop Trans-Auricular Vagus Nerve Stimulation System
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis Relapsing Remitting, Treatment
Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration
This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis
- Trial name
- IN-DXM-EMRR (NCT06223074)
- Testing
- IV Methylprednisolone administration, Nasal Methylprednisolone (MT)
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Universidad Nacional Autonoma de Mexico